SPRB
SPRB
NASDAQ · Biotechnology

Spruce Biosciences Inc

$68.98
+3.63 (+5.55%)
As of Apr 1, 3:16 PM ET ·
Financial Highlights (FY 2026)
Revenue
10.25M
Net Income
-110,695,812
Gross Margin
Profit Margin
-1,079.9%
Rev Growth
D/E Ratio
0.06
Revenue & Net Income
Margin Trends
FY 2026 FY 2025 FY 2024 FY 2023
Gross Margin 50.8% 50.8% 50.8%
Operating Margin -1,143.4% 3.7% 3.4% 3.3%
Profit Margin -1,079.9% 3.6% 2.9% 3.4%
Income Statement
FY 2026 FY 2025 FY 2024 FY 2023
Revenue 10.25M 53.02M 47.19M 56.70M
Gross Profit 26.94M 23.97M 28.80M
Operating Income -117,196,911 1.99M 1.61M 1.89M
Net Income -110,695,812 1.91M 1.39M 1.91M
Gross Margin 50.8% 50.8% 50.8%
Operating Margin -1,143.4% 3.7% 3.4% 3.3%
Profit Margin -1,079.9% 3.6% 2.9% 3.4%
Rev Growth +15.8% -2.9% 0.0%
Balance Sheet
FY 2026 FY 2025 FY 2024 FY 2023
Total Debt 1.64M 23.56M 23.83M 28.52M
Total Equity 27.14M 50.79M 49.45M 51.98M
D/E Ratio 0.06 0.46 0.48 0.55
Cash Flow
FY 2026 FY 2025 FY 2024 FY 2023
EBITDA -109,958,977 2.67M 2.51M 2.71M
Free Cash Flow 1.24M 802.3K 1.02M